Clinical Practice Guideline: Anticoagulation Reversal: Factor Xa Inhibitors - Rivaroxaban (Xarelto®), Apixaban (Eliquis®), Edoxaban (Savaysa®)

Brief Description: The guideline aims to provide recommendations for managing minor, major, and life-threatening bleeds in patients on factor Xa inhibitors. There is no pharmacologic antidote for factor Xa inhibitors, and treatment of bleeding remains empirical.

Variants
Price
$100.00